Design Therapeutics (DSGN) Treasury Shares (2020)

Design Therapeutics (DSGN) reported Treasury Shares of $22.0 million for Q4 2020, little changed sequentially from $22.0 million in Q3 2020.

Design Therapeutics (DSGN) Treasury Shares (2020) Analysis & Trends

Design Therapeutics (DSGN) has 1 years of Treasury Shares data on file, last reported at $22.0 million in Q4 2020.

For the quarter ending Q4 2020, Treasury Shares changed N/A year-over-year to $22.0 million; the trailing twelve-month figure through Dec 2020 stood at $22.0 million (changed N/A YoY), and the FY2020 full-year result was $22.0 million, changed N/A from the prior year.
Treasury Shares steadied at $22.0 million in Q4 2020, from $22.0 million in the prior quarter.
In the past five years, Treasury Shares ranged from a high of $22.0 million in Q1 2020 to a low of $22.0 million in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-21,709.08
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	265,401.92
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	19.41 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	5.14 Mn
10	Design Therapeutics	714.48 Mn	491.66 Mn	-	-

Download Data